Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China

Fineline Cube Jan 17, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...

Company Deals

Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals

Fineline Cube Jan 17, 2024

Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...

Company Drug

Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China

Fineline Cube Jan 17, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers

Fineline Cube Jan 17, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi...

Company Deals

Wuhan EasyDiagnosis Biomedicine Partners with Ailex Technology Group for Global Glycated Hemoglobin Testing Market

Fineline Cube Jan 17, 2024

Wuhan EasyDiagnosis Biomedicine Co., Ltd (SHE: 002932), a Chinese biomedicine company, has announced a strategic...

Company Drug

RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China

Fineline Cube Jan 17, 2024

RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...

Company Legal / IP

WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent

Fineline Cube Jan 17, 2024

WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...

Company Drug

Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome

Fineline Cube Jan 17, 2024

Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...

Company Deals

SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China

Fineline Cube Jan 17, 2024

SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...

Company Deals

Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution

Fineline Cube Jan 17, 2024

Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based...

Company Deals

XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China

Fineline Cube Jan 17, 2024

Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...

Company Drug

InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248

Fineline Cube Jan 17, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...

Company Drug

Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001

Fineline Cube Jan 17, 2024

China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...

Company Deals

Mindray Partners with WakeMed for Comprehensive Patient Monitoring Solutions

Fineline Cube Jan 16, 2024

Shenzhen-based medtech company Mindray has announced a procurement agreement with WakeMed Health & Hospitals in...

Company Drug

3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors

Fineline Cube Jan 16, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...

Company Drug

Hope Medicine Initiates Phase II Trial for HMI-115 in Endometriosis Treatment

Fineline Cube Jan 16, 2024

Hope Medicine Inc., based in China, has announced the first patient dosing in a global...

Company Drug

Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China

Fineline Cube Jan 16, 2024

Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...

Company

AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit

Fineline Cube Jan 16, 2024

AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...

Company Drug

SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer

Fineline Cube Jan 16, 2024

SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...

Policy / Regulatory

China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy

Fineline Cube Jan 16, 2024

The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...

Posts pagination

1 … 467 468 469 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.